

Article

Microbiota Composition of Breast Milk from Women of Different Ethnicity from the Manawatu—Wanganui Region of New Zealand

Christine A. Butts ^{1,*}, Gunaranjan Paturi ², Paul Blatchford ^{1,3}, Kerry L. Bentley-Hewitt ¹, Duncan I. Hedderley ¹, Sheridan Martell ¹, Hannah Dinnan ¹, Sarah L. Eady ⁴, Alison J. Wallace ⁴, Sarah Glyn-Jones ⁵, Frank Wiens ^{6,7}, Bernd Stahl ^{6,8} and Pramod Gopal ¹

- ¹ The New Zealand Institute for Plant and Food Research Limited, Private Bag 11600, Palmerston North 4442, New Zealand; paul.blatchford@zespri.com (P.B.); kerry.bentley-hewitt@plantandfood.co.nz (K.L.B.-H.); duncan.hedderley@plantandfood.co.nz (D.I.H.); sheridan.martell@plantandfood.co.nz (S.M.); hannah.dinnan@plantandfood.co.nz (H.D.); pramod.gopal@plantandfood.co.nz (P.G.)
- ² The New Zealand Institute for Plant and Food Research Limited, Private Bag 92169, Auckland 1142, New Zealand; gunaranjan.paturi@plantandfood.co.nz
- ³ Zespri International Limited, 400 Maunganui Road, Mt Maunganui 3149, New Zealand
- ⁴ The New Zealand Institute for Plant and Food Research Limited, Private Bag 4704, Christchurch 8140, New Zealand; sarah.eady@plantandfood.co.nz (S.L.E.); alison.wallace@plantandfood.co.nz (A.J.W.)
- ⁵ Nutricia New Zealand, 56-58 Aintree Avenue, Mangere, Auckland 2022, New Zealand; sarah.glyn-jones@danone.com
- ⁶ Danone Nutricia Research, Uppsalalaan 12, 3584 CT Utrecht, The Netherlands; frank.wiens@danone.com (F.W.); bernd.stahl@danone.com (B.S.)
- ⁷ Human Nutrition & Health, DSM Nutritional Products, P.O. Box 2676, CH-4002 Basel, Switzerland
- ⁸ Utrecht Institute for Pharmaceutical Sciences, Department of Chemical Biology & Drug Discovery, Utrecht University, Universiteitsweg 99, 3584 CG Utrecht, The Netherlands
- * Correspondence: chrissie.butts@plantandfood.co.nz

Received: 22 May 2020; Accepted: 10 June 2020; Published: 11 June 2020



Abstract: Human breastmilk components, the microbiota and immune modulatory proteins have vital roles in infant gut and immune development. In a population of breastfeeding women (n = 78) of different ethnicities (Asian, Māori and Pacific Island, New Zealand European) and their infants living in the Manawatu–Wanganui region of New Zealand, we examined the microbiota and immune modulatory proteins in the breast milk, and the fecal microbiota of mothers and infants. Breast milk and fecal samples were collected over a one-week period during the six to eight weeks postpartum. Breast milk microbiota differed between the ethnic groups. However, these differences had no influence on the infant's gut microbiota composition. Based on the body mass index (BMI) classifications, the mother's breast milk and fecal microbiota compositions were similar between normal, overweight and obese individuals, and their infant's fecal microbiota composition also did not differ. The relative abundance of bacteria belonging to the Bacteroidetes phylum was higher in feces of infants born through vaginal delivery. However, the bacterial abundance of this phylum in the mother's breast milk or feces was similar between women who delivered vaginally or by cesarean section. Several immune modulatory proteins including cytokines, growth factors, and immunoglobulin differed between the BMI and ethnicity groups. Transforming growth factor beta 1 and 2 (TGF β 1, TGF β 2) were present in higher concentrations in the milk from overweight mothers compared to those of normal weight. The TGF β 1 and soluble cluster of differentiation 14 (sCD14) concentrations were significantly higher in the breast milk from Māori and Pacific Island women compared with women from Asian and NZ European ethnicities. This study explores the relationship between ethnicity, body mass index, mode of baby delivery and the microbiota of infants and their mothers and their potential impact on infant health.



2 of 17

Keywords: human milk; breastfeeding; ethnicity; microbiota; immune modulators

1. Introduction

The gut microbiota has a dynamic role in maintaining host health by preventing the colonization of pathogenic bacteria and maintaining mucosal immunity [1]. The initial microbial colonization of the infant gut may begin before birth [2], but is further established during the birth process and through various transmission routes from the mother and the environment [3,4]. One of the major determinants of infant gut microbiota composition initially is mode of birth, whereby babies delivered vaginally come into contact with the maternal bacteria through the maternal feces and birth canal, though other factors are important including birth environment, prematurity, hygiene, mother-infant contact and the method of infant feeding. Further, maternal metabolic health can influence the infant gut microbiota composition and its related health outcomes [5]. Breast milk has been found to contain several bacterial groups with *Bifidobacteriaceae*, *Streptococcaceae* and *Staphylococcaceae* families being members of the core breast milk microbiome [6,7]. The microbiomes in the mother's breast milk and infant feces are closely related [8,9], emphasizing the route of transmission from mother's milk to the infant gut. Moreover, the mother's breast milk is important in shaping the infant gut microbiome for better health outcomes later in life.

In addition to the nutritional components, breast milk contains immune bioactive factors [10]. These include regulatory cytokines, growth factors, peptides, fatty acids and oligosaccharides and their presence is thought to support innate immunity and direct the development of adaptive immunity in the infant in the early weeks of life when breast milk is the sole source of nutrition [11–13]. Large quantities of secretory immunoglobulin (Ig) A are present in breast milk. The IgA antibodies are capable of neutralizing the pathogens prior to binding and infecting the infant cells [14]. The secretory IgA antibodies present in breast milk confer immunological protection to the infant during the first few months of life and are part of the establishment of long-term intestinal homeostasis by regulating gut microbiota composition and gene expression in the intestinal epithelial cells [15].

There is limited information on human breast milk composition with regard to ethnicity and the effect this may have on bacterial populations and immune modulatory proteins present in the milk. In the present study, microbiota composition and immune modulatory protein concentrations in breast milk from women of different ethnic groups living in New Zealand (NZ) were examined. In addition, fecal microbiota composition in the infants was also examined to determine whether there is a relationship between the mother's breast milk and infant gut bacterial populations. The main ethnic groups in NZ are the indigenous Māori (15%) and three major immigrant populations from the Pacific Islands (7%), Asia (12%) and Europe (74%) [16].

2. Materials and Methods

2.1. Study Design

The study protocol was approved by the NZ Human Disability and Ethics Committee (Application number 13/CEN/79/AM01) and was conducted in accordance with the Declaration of Helsinki. The study design has been described previously by Butts et al. [17]. Briefly, breast feeding women (aged 18–55 years) permanently living in the Manawatu–Wanganui region of the North Island of NZ were sought. One hundred and forty-six participants were screened, sixty-six participants who did not meet the recruitment criteria were excluded from the study, and the remaining eighty participants fulfilling the inclusion and exclusion criteria and who gave written consent were recruited into the study (Figure 1). The ethnicities of these women were Asian, Māori and Pacific Island, and Europeans. They each provided three breast milk samples (approximately 50 mL per sample) over a one-week period between six and eight weeks postpartum. These samples from each mother were immediately frozen

in household freezers at -18 °C, brought to the laboratory within 12 h of collection of the last sample, thawed, pooled, aliquoted into smaller volumes, and then refrozen at -80 °C until analysis. In addition, fecal samples from the mother and the infant were also collected within the same week and frozen at -80 °C until analysis.



Figure 1. Flow chart of the participant recruitment into the study.

2.2. Microbiota Quantification

A 1 mL aliquot of each of the pooled breast milk samples from each individual was thawed to 5 °C prior to centrifugation at 7200 × g for 20 min to separate the fat, supernatant and pellet. A sterile spatula was used to remove the fat layer. The supernatant was removed leaving behind the pellet, which was re-suspended in 750 μ L of bead-beating solution from the PowerLyzer PowerSoil DNA isolation kit (MO BIO Laboratories, Carlsbad, CA, USA). The re-suspended pellet and bead-beating solution were then transferred into a tube. A 0.25 g (±10%) portion of each fecal sample from mothers and infants was weighed into a sterile bead-beating tube. The DNA extraction for each sample was undertaken using the PowerLyzer PowerSoil DNA isolation kit (MO BIO Laboratories, Carlsbad, CA, USA) according to the manufacturer's instructions. The bead-beating protocol was slightly modified, where a Disruptor Genie (Scientific Industries Inc., Bohemia, NY, USA) was used for 30 s followed by transferring the samples onto ice for 1 min; this process was repeated three times.

The PCR reactions were performed to target the V3–V4 hypervariable region of the 16s rRNA gene using the following primers [18]:

Forward: Bakt_341F-TCGTCGGCAGCGTCAGATGTGTATAAGAGACAG<u>CCTACGGGNGGCW</u> <u>GCAG</u>

and Reverse: Bakt_805R-GTCTCGTGGGGCTCGGAGATGTGTATAAGAGACAG<u>GACTACHVGG</u> GTATCTAATCC.

The underlined sequence binds to the amplicon region of interest, whereas the remaining primer sequence binds to the Illumina index adaptors. The PCR conditions employed for breast milk and fecal bacterial DNA were slightly different. For breast milk samples, each PCR run consisted of $25 \,\mu\text{L}$ of HotStartTaq master mix (Qiagen, Melbourne, Australia), $11.5 \,\mu\text{L}$ of each of the forward and reverse primers and 2 µL of template DNA or sterile water (negative control), equaling 50 µL total volume. The PCR conditions were: initial denaturation of 95 °C for 15 min followed by 35 cycles of 30 s denaturation at 95 °C, 30 s annealing at 55 °C and 30 s extension at 72 °C, then lastly 5 min extension at 72 °C. For fecal samples, each PCR run consisted of 25 μ L of HotStartTaq master mix (Qiagen), 12 µL of each of the forward and reverse primers and 1 µL of template DNA or sterile water (negative control) equaling 50 µL total volume. The PCR conditions were: initial denaturation of 95 °C for 15 min followed by 30 cycles of 30 s denaturation at 95 °C, 30 s annealing at 55 °C and 30 s extension at 72 °C, then lastly 5 min extension at 72 °C. The purification of PCR products was undertaken using a QIAquick PCR purification kit (Qiagen). The Qubit 2.0 Fluorometer (Life Technologies, Carlsbad, CA, USA) was used to quantify the PCR products before they were sent to the NZ Genomics Ltd. (Massey Genome Service, Palmerston North, NZ) for the second PCR step. The amplicons were library quality control checked, diluted and pooled prior to being sequenced on the Illumina MiSeq instrument $(2 \times 250 \text{ bp paired-end reads}).$

Quantitative Insights into Microbial Ecology (QIIME) software V1.8.0 was used to analyze the Illumina MiSeq sequencing data [19]. To assemble the forward and reverse reads into a continuous sequence, PANDASeq was used with parameters of at least 40 bp overlap, a minimum of 350 bp in length and a maximum of 500 bp in length [20]. The split_libraries.py script was run to enable assignment of appropriate sample names against each read. Chimeras were filtered from the sequences and the reads clustered into operational taxonomic units (OTUs) based on a 97% identity threshold value using USEARCH [21,22]. Alignment of the sequences was carried out using PyNAST [23] with reference to the Greengenes core reference database (version 13_8) [24]. Alpha rarefaction was calculated using the Phylogenetic Diversity, Chao1, Observed Species and Shannon diversity metrics to a rarefaction depth of 10,000 sequences. Beta diversity was determined using UniFrac distances as input and EMPeror to visualize 3D relationships [25,26].

2.3. Immune and Growth Factor Assays

The amounts of IgA, transforming growth factor (TGF)- β 1 and - β 2, insulin-like growth factor (IGF)-1, soluble cluster of differentiation 14 (CD14), interleukin (IL)-2, IL-4, IL-6, IL-7, IL-8, IL-10 and interferon (IFN)- γ were measured in the breast milk samples as supplied by the mothers. Two 1 mL aliquots of each of the pooled breast milk samples from each individual were thawed at room temperature prior to sodium taurocholate and whey extractions. An equal volume of 12 mmol/L sodium taurocholate (synthesized from cholic acid) was added to thawed milk samples, incubated for 30 min and centrifuged at 12,000× *g* for 10 min at room temperature. Intermediate fractions (between the fat layer and pellet) were used in Cytometric Bead Arrays, TGF β 2 ELISA and IgA ELISA assays. Whey was prepared by centrifuging thawed milk at 800× *g* for 10 min at 4 °C and the supernatant was collected. The whey fractions were used to measure TGF β 1 and IGF-1. Cytometric Bead Array was used for soluble human proteins, along with Flex sets for human soluble CD14, IL-2, IL-4, IL-6, IL-7, IL-8, IL-10 and IFN- γ according to the manufacturer's instructions.

The dilutions used for each protein were: IgA 1/5000, TGF β 1 1/2, TGF β 2 and IGF-1 ELISA assays were undiluted, and then for the cytometric bead array, SCD14 was diluted 1/5000, whilst all other proteins were run undiluted. These dilutions ensured that the concentrations in the samples were within the concentration ranges of the standard curves. IgA, TGF β 1, TGF β 2 and IGF-1 in breast milk

were quantified by using the respective ELISA kits according to the manufacturer's instructions. IgA was determined using the Human IgA ELISA quantitation and ELISA starter accessory kit (E80-102 and E101, Bethyl laboratories, Montgomery, TX, USA), with a minimal detectable concentration of 7.8 ng/mL, an intra-assay precision of <5% and an inter-assay precision of <10%. TGFβ1 was determined using the LEGEND MAXTM Total TGFβ1 ELISA kit (Biolegend, San Diego, CA, USA, Cat No: 436707), with a minimal detectable concentration of 3.5 pg/mL, an intra-assay precision of <4% and an inter-assay precision of <7%. TGFβ2 was determined using a human TGFβ2 ELISA kit (Cusabio Life Science, Wuhan, China, Cat No: CSB-E09783h), with a minimal detectable concentration of 7.81 pg/mL, an intra-assay precision of <8% and an inter-assay precision of <10%. IGF-1 was determined using the Human IGF-1 ELISA kit (Cusabio Life Science, Wuhan, China, Cat No: CSB-E09783h), with a minimal detectable concentration of 1.95 ng/mL, an intra-assay precision of <8% and an inter-assay precision of <8% and an inter-assay precision of <10%. IGF-1 was determined using the Human IGF-1 ELISA kit (Cusabio Life Science, Wuhan, China, Cat No: CSB-E04580h), with a minimal detectable concentration of 1.95 ng/mL, an intra-assay precision of <8% and an inter-assay precision of <8% and an inter-assay precision of <10%. IL-2, IL-4, IL-6, IL-7, IL-8, IL-10 and IFN-γ were determined (Super-X PlexTM cytokine assay, Antigenix America Inc., Melville, NY, USA), with minimal detectable concentrations of 3 pg/mL (IL-2), 1 pg/mL (IL-4), 5 pg/mL (IL-6), 5 pg/mL (IL-7), 1 pg/mL (IL-8), 2 pg/mL (IL-10) and 3 pg/mL (IFN-γ), an intra-assay precision of <10% and an inter-assay precision <20%.

2.4. Statistical Analysis

Summary statistics (means and standard errors) were calculated for each of the ethnic groups. The relative bacterial abundance in breast milk, the mother's feces and the infant's feces were skewed, so Kruskal–Wallis non-parametric analysis of variance (ANOVA) was applied. Only genera where the relative abundance was greater than 0.5% in at least one sample were analyzed. The immunology data were also skewed, so ethnic groups were compared using Kruskal–Wallis non-parametric ANOVA; where there was a significant difference between groups, multiple comparisons were done using the Conover-Iman method. In recognition of the number of variables being tested, the ANOVA *p*-values form each data set (immune-related proteins, maternal bacteria, infant bacteria, categorized by ethnicity, maternal body mass index (BMI) or delivery method) were adjusted using the Benjamini–Hochberg (BH) false discovery method. Kruskall–Wallis analyses were carried out using Genstat (version 17, VSNi Ltd., Hemel Hempstead, UK). The Benjamini–Hochberg adjustment was carried out using the *p*.adjust procedure in the stats package of R (The R Foundation for Statistical Computing, Vienna, Austria).

3. Results

3.1. Study Participants

The demographics and baseline characteristics of the study participants were reported earlier in Butts et al. [17] and Supplementary Table S1. From eighty participants, seventy eight completed the study—53 NZ European, 17 Māori and Pacific Island and 8 Asian women (Supplementary Table S2). When the participants were categorized according to the BMI classifications outlined by the Ministry of Health, NZ [27], 27 were normal weight, 31 overweight and 20 obese (Supplementary Tables S3 and S4). At six weeks postpartum, many mothers will retain some of the weight they gained during pregnancy. When the participants were categorized according to the mode of delivery, 14 were by cesarean and 63 by vaginal delivery for the bacterial analyses, whereas there were 14 by cesarean and 64 by vaginal delivery for the immune modulatory proteins.

3.2. Microbiota

At the phylum level, no significant differences (p > 0.05) in bacterial populations were observed between ethnicities in breast milk and fecal samples of mothers (Figure 2). Similarly, there were no significant differences (p > 0.05) in infant fecal bacteria analyzed by maternal ethnicity. The bacterial abundance in breast milk, mother and infant feces at the genus level are shown in Tables 1–3. In breast milk, the most prevalent bacteria were *Ruminococcaceae*, *Bifidobacterium* and *Lachnospiraceae*. The most prevalent bacteria in the mother's feces were *Ruminococcaceae*, *Bacteroides* and *Lachnospiraceae*, whereas, in the infant feces, *Bifidobacterium and Bacteroides* were the most prevalent bacteria.



Figure 2. Relative abundance of bacteria at the phylum level in mother and infant. The data were categorized according to the mother's ethnicity.

Table 1. Relative abundance of bacteria at	the genus leve	el in breast milk	categorized	according to the
mother's ethnicity.				

	Asian	Māori and Pacific Island	New Zealand European	Benjamini–Hochberg- Adjusted <i>p</i> Value
Actinomyces	0.48 ± 0.47	0.12 ± 0.10	0.46 ± 0.25	0.969
Agrobacterium	1.20 ± 0.95	0.09 ± 0.07	0.85 ± 0.64	0.858
Akkermansia	2.34 ± 1.14	3.01 ± 0.68	1.41 ± 0.29	0.376
Anaerococcus	0.15 ± 0.15	0.11 ± 0.07	0.26 ± 0.14	0.969
Anaerostipes	0	0.10 ± 0.10	0.03 ± 0.03	0.376
Atopobium	0.66 ± 0.65	0.54 ± 0.53	0.19 ± 0.11	0.980
Bacteroidales_S24_7	0.02 ± 0.02	0.12 ± 0.07	0.03 ± 0.01	0.773
Bacteroides	1.63 ± 0.80	3.88 ± 1.04	2.61 ± 0.50	0.748
Barnesiellaceae	0.04 ± 0.03	0.04 ± 0.03	0.05 ± 0.03	0.969
Bifidobacteriaceae	0.01 ± 0.01	0.25 ± 0.20	0.06 ± 0.04	0.969
Bifidobacterium	6.38 ± 2.26	6.08 ± 1.10	7.87 ± 1.01	0.897
Blautia	2.68 ± 0.90	3.97 ± 0.60	2.15 ± 0.27	0.376
Brevundimonas	0.01 ± 0.01	0.15 ± 0.14	0.21 ± 0.20	0.748
Caulobacteraceae	1.12 ± 0.95	0.88 ± 0.69	1.28 ± 0.51	0.531
Christensenella	0	0	0.04 ± 0.04	0.865
Christensenellaceae	0.39 ± 0.37	0.48 ± 0.15	0.21 ± 0.05	0.390
Chryseobacterium	0.06 ± 0.03	2.90 ± 2.81	2.39 ± 1.22	0.969
Clostridiaceae	0.70 ± 0.46	1.24 ± 0.35	0.93 ± 0.17	0.682
Clostridiaceae_Other	0.02 ± 0.02	0.24 ± 0.12	0.15 ± 0.05	0.969
Clostridiales	3.41 ± 1.38	4.38 ± 0.74	2.53 ± 0.36	0.402
Clostriaiales_Other	0.89 ± 0.47	0.47 ± 0.11	0.48 ± 0.10	0.782
Clostridium	1.12 ± 0.74	2.00 ± 1.05	0.88 ± 0.25	0.460
Coninsena	0.92 ± 0.35	1.09 ± 0.23	1.23 ± 0.17 1.72 + 0.28	0.969
Coprococcus	2.13 ± 0.83	1.89 ± 0.38	1.75 ± 0.28	0.865
Coriobacteriaceae	0.56 ± 0.33	0.57 ± 0.17	0.25 ± 0.07	0.396
Dorra	0.69 ± 0.34	2.92 ± 2.13	4.02 ± 1.20	0.969
Doreu Elizabathleinaia	0.31 ± 0.37	1.00 ± 0.30	0.00 ± 0.20	0.376
Enterobactoriaceae	10.2 ± 10.0 0.15 ± 0.15	0.03 ± 0.02	0.02 ± 0.01 0.20 ± 0.12	0.403
Enterobucieriuceue	0.15 ± 0.15	0.04 ± 0.02	0.20 ± 0.13	0.969
Epuiopiscium Faecalihacterium	0.52 ± 0.27	1.70 ± 0.28	0.02 ± 0.02 0.89 ± 0.15	0.376
Finegoldia	0.02 ± 0.27 0.03 ± 0.03	1.70 ± 0.20 0.03 ± 0.03	0.09 ± 0.13 0.16 ± 0.08	0.460
Fusohacterium	0.05 ± 0.05 0.75 ± 0.45	0.03 ± 0.03	0.10 ± 0.00 0.49 ± 0.19	0.400
Lachnosnira	1.27 ± 0.63	1.45 ± 0.62	0.78 ± 0.17	0.518
Lachnospiraceae	4.27 ± 0.00	6.80 ± 0.02	5.05 ± 0.82	0.461
Lachnospiraceae Other	0.14 ± 0.05	1.11 ± 0.37	0.29 ± 0.07	0.177
Leucobacter	0	0	0.26 ± 0.23	0.773
Micrococcaceae	0	0.01 ± 0.00	0.04 ± 0.04	0.461
Micrococcus	0.01 ± 0.01	0	0.07 ± 0.05	0.773
Mogibacteriaceae	0.16 ± 0.12	0	0.10 ± 0.07	0.714
Ödoribacter	0	0	0.04 ± 0.04	0.461
Oscillospira	0.63 ± 0.46	0.65 ± 0.20	0.56 ± 0.14	0.599
Parabacteroides	0.26 ± 0.17	0.33 ± 0.12	0.29 ± 0.09	0.858
Peptostreptococcus	0.29 ± 0.19	0.04 ± 0.04	0.39 ± 0.14	0.402
Porphyromonas	0.17 ± 0.17	0	0.13 ± 0.09	0.682
Prevotella	0.01 ± 0.01	0.08 ± 0.03	0.27 ± 0.13	0.748
Propionibacterium	6.07 ± 5.15	0.35 ± 0.10	0.27 ± 0.09	0.390
Pseudomonas	0.28 ± 0.16	4.31 ± 3.04	0.96 ± 0.56	0.854
Rikenellaceae	1.92 ± 1.52	6.98 ± 1.92	2.01 ± 0.60	0.710
Roseburia	0.52 ± 0.28	0.56 ± 0.22	0.46 ± 0.12	0.969
Rothia	3.10 ± 1.78	0.83 ± 0.40	1.94 ± 0.76	0.969
Ruminococcaceae	10.7 ± 4.13	17.2 ± 2.05	10.2 ± 1.51	0.390
[Ruminococcus]	1.17 ± 0.80	1.32 ± 0.37	0.83 ± 0.30	0.376
Ruminococcus	2.05 ± 0.84	3.03 ± 0.68	1.49 ± 0.26	0.376
Sphingobium	0.11 ± 0.10	0.10 ± 0.05	0.83 ± 0.43	0.390
Sphingomonas	0.21 ± 0.09	0.41 ± 0.26	0.52 ± 0.15	0.969
Streptophyta	0.22 ± 0.21	0.10 ± 0.06	0.24 ± 0.09	0.748
Unassigned	1.51 ± 0.30	3.62 ± 1.24	2.20 ± 0.47	0.682
Veillonella	0.07 ± 0.05	0.02 ± 0.01	0.27 ± 0.08	

Data expressed as the mean \pm standard error of the mean. Some taxonomy could not be identified at the genus level. Square brackets around a genus name indicate a candidate genus.

Table 2. Relative abundance of bacteria at the genus level in the mother's feces categorized according
to the ethnicity.

	Asian	Māori and Pacific Island	New Zealand European	Benjamini–Hochberg- Adjusted <i>p</i> Value
Actinomuces	0	0	0.01 ± 0.01	0.471
Agrobacterium	õ	0	0.04 ± 0.04	0.499
Akkermansia	142 ± 0.84	242 ± 0.78	3.17 ± 1.02	0.453
Angerococcus	0	0.01 ± 0.01	0.03 ± 0.03	0.257
Anaerostines	0.07 ± 0.05	0.08 ± 0.03	0.08 ± 0.04	0.453
Bacteroidales	0	0.33 ± 0.33	0.10 ± 0.10	0.894
Bacteroidales S24 7	0	0.09 ± 0.08	0.83 ± 0.43	0.629
Bacteroides	20.5 ± 7.53	16.6 ± 4.30	17.4 ± 2.25	0.894
Barnesiellaceae	0.38 ± 0.19	1.19 ± 0.51	0.96 ± 0.19	0.931
Bifidobacterium	2.22 ± 0.88	3.65 ± 1.42	1.57 ± 0.31	0.240
Blautia	1.94 ± 0.46	3.25 ± 1.11	2.73 ± 0.33	0.748
Buturicimonas	0.10 ± 0.04	0.08 ± 0.04	0.13 ± 0.05	0.629
Caulobacteraceae	0.07 ± 0.07	0	0.31 ± 0.09	0.240
Christensenellaceae	0.50 ± 0.47	0.48 ± 0.16	0.55 ± 0.09	0.240
Clostridiaceae	0.16 ± 0.08	0.60 ± 0.21	0.34 ± 0.07	0.240
Clostridiaceae Other	0.03 ± 0.02	0.11 ± 0.07	0.03 ± 0.01	0.894
Clostridiales	4.90 ± 1.61	3.25 ± 0.89	5.49 ± 0.54	0.240
Clostridiales Other	0.85 ± 0.25	0.49 ± 0.10	0.98 ± 0.16	0.453
Clostridium	0.40 ± 0.13	0.22 ± 0.04	0.34 ± 0.03	0.407
Collinsella	0.36 ± 0.09	1.44 ± 0.53	0.64 ± 0.10	0.352
Coprococcus	3.10 ± 0.45	2.63 ± 0.60	2.81 ± 0.42	0.580
Coriobacteriaceae	0.11 ± 0.06	0.32 ± 0.07	0.37 ± 0.08	0.294
Dorea	0.45 ± 0.14	1.35 ± 0.45	0.58 ± 0.10	0.240
Eggerthella	0.03 ± 0.01	0.04 ± 0.02	0.06 ± 0.02	0.986
Enterobacteriaceae	0	0.01 ± 0.01	0.10 ± 0.04	0.453
Evuloviscium	0	0	0.11 ± 0.11	0.580
Faecalibacterium	2.39 ± 0.87	1.69 ± 0.33	1.44 ± 0.28	0.352
Finegoldia	0.21 ± 0.21	0.02 ± 0.02	0.20 ± 0.04	0.453
Fusobacterium	0	2.71 ± 2.69	0.02 ± 0.01	0.629
Lachnospira	2.62 ± 0.96	2.01 ± 1.00	1.45 ± 0.38	0.320
Lachnospiraceae	7.24 ± 1.61	6.20 ± 1.15	6.05 ± 0.88	0.664
Lachnospiraceae_Other	0.49 ± 0.14	0.75 ± 0.13	0.42 ± 0.07	0.240
Mogibacteriaceae	0.04 ± 0.04	0.10 ± 0.05	0.05 ± 0.01	0.748
Ödoribacter	0.10 ± 0.06	0.19 ± 0.09	0.19 ± 0.04	0.663
Oscillospira	0.47 ± 0.17	0.84 ± 0.17	0.88 ± 0.20	0.664
Parabacteroides	1.03 ± 0.45	1.71 ± 0.53	1.67 ± 0.39	0.926
Paraprevotella	0	0.49 ± 0.29	0.46 ± 0.37	0.240
Porphyromonas	0.02 ± 0.01	0	0.03 ± 0.02	0.472
Prevotella	5.58 ± 5.57	2.38 ± 2.16	0.826 ± 0.26	0.748
Rikenellaceae	1.05 ± 0.34	2.64 ± 0.86	3.51 ± 0.58	0.626
Rikenellaceae_Other	0	0	0.02 ± 0.01	0.240
Roseburia	2.13 ± 1.75	0.75 ± 0.40	0.40 ± 0.12	0.664
Ruminococcaceae	26.1 ± 6.54	26.4 ± 3.88	19.1 ± 2.70	0.406
[Ruminococcus]	0.41 ± 0.14	2.38 ± 1.52	0.86 ± 0.19	0.294
Ruminococcus	4.05 ± 1.71	3.93 ± 1.09	3.26 ± 0.61	0.627
Sphingomonas	0.01 ± 0.01	0	0.03 ± 0.01	0.240
Sutterella	0.12 ± 0.06	0.02 ± 0.01	0.09 ± 0.05	0.453
Unassigned	2.06 ± 0.21	2.29 ± 0.27	2.11 ± 0.17	0.580
Veillonella	0.95 ± 0.95	0.09 ± 0.09	2.25 ± 0.63	0.254

Data expressed as the mean ± standard error of the mean. Some taxonomy could not be identified at the genus level. Square brackets around a genus name indicate a candidate genus.

	Asian	Māori and Pacific Island	New Zealand European	Benjamini–Hochberg- Adjusted <i>p</i> Value
Actinomyces	0.01 ± 0.006	0.02 ± 0.02	1.31 ± 0.86	0.706
Agrobacterium	0	0.005 ± 0.005	0.07 ± 0.05	0.706
Akkermansia	0.39 ± 0.37	0.07 ± 0.05	0.01 ± 0.01	0.706
Anaerotruncus	0	0	0.02 ± 0.02	0.706
Bacteroides	20.1 ± 10.8	24.12 ± 7.52	16.01 ± 3.57	0.706
Bifidobacterium	60.1 ± 12.4	50.4 ± 8.270	41.2 ± 4.94	0.706
Blautia	0.23 ± 0.19	0.12 ± 0.06	0.48 ± 0.24	0.965
Caulobacteraceae	0	0	1.74 ± 1.16	0.706
Clostridiaceae	6.13 ± 6.00	2.80 ± 2.69	3.14 ± 1.84	0.706
Clostridiaceae_Other	0	0.01 ± 0.01	0.02 ± 0.02	0.936
Clostridiales	0.43 ± 0.37	0.12 ± 0.08	0.45 ± 0.31	0.706
Clostridiales_Other	0.02 ± 0.01	0.02 ± 0.01	0.08 ± 0.04	0.706
Clostridium	0.18 ± 0.09	6.21 ± 5.78	14.3 ± 4.16	0.706
Collinsella	3.70 ± 3.42	2.47 ± 1.05	2.49 ± 1.08	0.706
Coprococcus	0.32 ± 0.28	0.08 ± 0.05	0.23 ± 0.10	0.706
Coriobacteriaceae	0.05 ± 0.03	0.23 ± 0.16	0.43 ± 0.36	0.706
Dorea	0.08 ± 0.06	0.07 ± 0.07	0.63 ± 0.49	0.719
Eggerthella	0.05 ± 0.04	0.12 ± 0.08	0.13 ± 0.06	0.706
Enterobacteriaceae	0.36 ± 0.30	0.35 ± 0.13	0.33 ± 0.07	0.706
Faecalibacterium	0.22 ± 0.19	0.09 ± 0.07	0.03 ± 0.01	0.706
Finegoldia	0.01 ± 0.01	0	0.04 ± 0.03	0.706
Fusobacterium	0.03 ± 0.03	0.03 ± 0.02	0.34 ± 0.33	0.706
Lachnospiraceae	1.11 ± 0.82	2.32 ± 1.65	0.80 ± 0.31	0.706
Lachnospiraceae_Other	0.02 ± 0.02	0.06 ± 0.02	0.68 ± 0.63	0.724
Megasphaera	0	0.36 ± 0.26	0.04 ± 0.04	0.706
Odoribacter	0	0	0.07 ± 0.05	0.706
Oscillospira	0.31 ± 0.27	0.01 ± 0.01	0.26 ± 0.13	0.706
Parabacteroides	0.22 ± 0.14	2.05 ± 1.07	2.57 ± 1.37	0.936
Peptostreptococcus	0.03 ± 0.03	0.13 ± 0.13	0.03 ± 0.03	0.936
Porphyromonas	0	0	0.06 ± 0.05	0.706
Prevotella	0.01 ± 0.01	0.03 ± 0.02	0.12 ± 0.08	0.936
Pseudoramibacter	0	0.22 ± 0.22	0.03 ± 0.03	0.833
Rikenellaceae	0.83 ± 0.83	0.01 ± 0.00	0.40 ± 0.18	0.706
Ruminococcaceae	0.92 ± 0.66	1.04 ± 0.61	1.39 ± 0.95	0.706
[Ruminococcus]	0.79 ± 0.73	1.85 ± 1.15	3.72 ± 1.83	0.706
Ruminococcus	0.51 ± 0.43	0.25 ± 0.18	0.09 ± 0.02	0.706
Sphingomonas	0.01 ± 0.01	0	0.27 ± 0.26	0.706
Unassigned	2.25 ± 0.60	3.56 ± 0.91	2.40 ± 0.26	0.706
Veillonella	0.01 ± 0.01	0.03 ± 0.01	0.54 ± 0.20	0.706

Table 3. Relative abundance of bacteria at the genus level in the infant's feces categorized according to the mother's ethnicity.

Data expressed as the mean \pm standard error of the mean. Some taxonomy could not be identified at the genus level. Square brackets around a genus name indicate a candidate genus.

The bacterial data were also analyzed based on BMI categories (normal, overweight and obese). At the phylum level, no significant differences (p > 0.05) in bacterial composition were observed in the mother's breast milk and feces, or in the infant feces (Figure 3). Similarly, no significant differences (p > 0.05) were observed in bacterial composition at the genus level in the mother's breast milk and feces, or in the infant feces (Supplementary Tables S5–S7).



Figure 3. Relative abundance of bacteria at the phylum level in mother and infant. The data were categorized according to the mother's body mass index.

The bacterial data were also analyzed based on mode of delivery (cesarean or vaginal). At the phylum level, there were no significant differences (p > 0.05) in bacterial composition of the mother's breast milk and feces who have delivered their babies through cesarean section or vaginally (Figure 4). At the genus level, there were no significant differences (p > 0.05) in bacterial composition of the

mother's breast milk and feces who have delivered their babies through cesarean section or vaginally (Supplementary Tables S8 and S9). Infants delivered vaginally had significantly higher numbers of *Collinsella* (p < 0.001) Supplementary Table S10).



Figure 4. Relative abundance of bacteria at the phylum level in mother and infant. The data were categorized according to the mode of delivery.

The immune modulatory proteins present in breast milk from the different ethnic groups are shown in Figure 5. The TGF β 1 and sCD14 concentrations were significantly higher in the breast milk from Māori and Pacific Island women compared with women from Asian and NZ European ethnicities (p < 0.05), whereas the IL-7 concentration was lower in the breast milk from Asian women compared to that of NZ European women (p < 0.05). Data analysis based on BMI categories showed that overweight women had significantly higher concentrations of TGF β 1 and TGF β 2 in their breast milk compared to those women who had normal body weight (Figure 6). No significant differences were found in the immune-related proteins within the milk of mothers who delivered their babies by cesarean section or vaginally (p > 0.05) (Supplementary Figure S1).



Figure 5. Immune-related proteins in the mother's breast milk categorized according to the ethnicity. Data expressed as the mean \pm standard error of the mean. Mean values with a different letter differ significantly, p < 0.05. IL—interleukin, IFN—interferon, IGF—insulin-like growth factor, TGF—transforming growth factor, sCD—soluble cluster of differentiation, and Ig—immunoglobulin.





Figure 6. Immune-related proteins in the mother's breast milk categorized according to the body mass index outlined by the Ministry of Health, New Zealand. Data expressed as the mean \pm standard error of the mean. Mean values with a different letter differ significantly, p < 0.05. IL—interleukin, IFN—interferon, IGF—insulin-like growth factor, TGF—transforming growth factor, sCD—soluble cluster of differentiation, and Ig—immunoglobulin.

4. Discussion

We examined the microbiota composition and immune modulatory proteins present in the breast milk of women from different ethnic backgrounds living in NZ. The microbiota in human milk is diverse, with the large inter-individual variation linked to geographical and lifestyle differences [28]. Studies have highlighted the importance of maternal diet in promoting infant health [29–31], and the vital role that bacteria and oligosaccharides in breast milk play in the development and functioning of

the infant's gut and immune system [13]. Breastfeeding is known to establish a diverse gut microbiota composition with a stable beneficial bacterial population in infants [32,33].

In the current study, we found no significant differences in bacteria abundances in the breast milk or fecal samples of mothers and infants when the data were compared by ethnicity, body mass and method of infant delivery. The mode of infant delivery is known to shape the structure of microbiota composition in infants. Previous studies have highlighted this by comparing the microbiota of infants delivered naturally through the vagina or by cesarean section [3,34]. In addition, the mode of delivery can have an impact on microbiota composition in maternal breast milk; cesarean section delivery was linked with reduced breast milk microbiota diversity and richness [7]. In the present study, when microbiota was analyzed according to the mode of delivery, the infants born through vaginal delivery had higher *Collinsella* genera in feces; although these differences were not evident in maternal breast milk or feces. An association between the abundance of gastrointestinal *Collinsella* spp. and body weight has been reported in earlier studies in overweight and obese pregnant women [35] and obese children [36].

The immune modulatory proteins present in breast milk contribute to the development of host defense mechanisms in the developing infant. They can have a range of impacts on infant health and their concentrations in breast milk are affected by maternal lifestyle factors, which are summarized in Supplementary Table S11. A balance of stimulatory and regulatory immune proteins is required to provide protection to the infant, whilst ensuring that inappropriate inflammation does not occur. Breast milk contains a number of factors that can impact mucosal immune function, including immune cells, antibodies, microbiota, oligosaccharides, cytokines, and soluble receptors. The concentrations of immune modulatory proteins found in the present study were highly variable. However, this has been reported previously in similar studies on breast milk [37–39]. This may be due to different methods of milk collection, including age of infant, time of milk collection, analytical method as well as population characteristics such as diet, gestation and exercise between and within studies [37,40]. In the present study, we limited this variability by collecting milk samples within a narrow infant age (6–8 weeks postpartum) and after the first feed of the day.

In the current study, we found that women of Māori and Pacific Island ethnicity had higher concentrations of TGF β 1 and sCD14 in their breast milk. IgA contributes to the exclusion of antigens in infants and its presence in breast milk is important while the infant's own intestinal IgA production is not fully developed [41]. TGF β has a role in IgA production, oral tolerance towards the infant's own gut microbiota and preventing adverse immune reactions in infants [42], while sCD14 is associated with reduced risk of allergy and obesity [43]. Increased TGF β 1 levels in the breast milk of mothers have been observed in those with greater exposure to infectious diseases in childhood [44,45]. We also observed that there were higher levels of IL-7 cytokine in the breast milk of NZ European women when compared with the breast milk of Asian women. There is evidence that cytokines such as interleukins and IFN- γ cross the intestinal barrier where they communicate with cells and influence immune activity [46], and that regulatory cytokines such as IL-7 in breast milk are capable of crossing the intestinal barrier and inducing the development of the thymus of the infants and enhancing the production of T cells [47,48]. The importance of this observation in the context of the present study is not clear, as little is known about the influence of ethnicity and lifestyle factors on breast milk cytokines.

5. Conclusions

This is the first study to examine the microbiota composition and immune modulatory proteins in human breast milk from different ethnic populations in NZ. This study also explored the relationship between ethnicity, and maternal and infant fecal microbiota compositions, providing foundation data for further research on maternal and infant nutrition and the long-term health of people in NZ.

Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6643/12/6/1756/s1, Table S1: Demographics and baseline characteristics of the study participants; Table S2: Demographics and baseline characteristics of the study participants according to ethnicity, Table S3; World Health Organization and

New Zealand Ministry of Health classifications of body mass index (kg/m²); Table S4: Demographics and baseline characteristics of the study participants according to body mass index (BMI) classifications outlined by Ministry of Health, New Zealand; Table S5: Relative abundance of bacteria at the genus level in the mother's breast milk categorized by body mass index; Table S6: Relative abundance of bacteria at the genus level in the mother's feces categorized according to the body mass index; Table S7: Relative abundance of bacteria at the genus level in the mother's feces categorized according to the mother's body mass index; Table S7: Relative abundance of bacteria at the genus level in the infant's feces categorized according to the mother's body mass index; Table S8: Relative abundance of bacteria at the genus level in the mother's breast milk categorized according to the mode of delivery; Table S9: Relative abundance of bacteria in the infant's feces at the genus level categorized according to the mode of delivery; Table S10: Relative abundance of bacteria in the infant's feces at the genus level categorized according to the mode of delivery; Table S11: Summary of immune modulatory proteins analyzed, their potential impact on infant health, and maternal diet and lifestyle influences affecting their concentrations in breast milk; Figure S1: Immune-related proteins in the mother's breast milk categorized according to the mode of delivery of infants.

Author Contributions: Data curation, C.A.B., G.P., P.B., K.L.B.-H., S.M. and H.D.; formal analysis, G.P., P.B., K.L.B.-H. and D.I.H.; investigation, C.A.B. and G.P.; methodology, G.P., P.B., K.L.B.-H., S.M., H.D., S.L.E. and A.J.W.; project administration, C.A.B. and S.G.-J.; resources, C.A.B.; visualization, G.P., writing—original draft preparation, C.A.B. and G.P.; writing—review and editing, C.A.B., G.P., P.B., K.L.B.-H., D.I.H., S.M., H.D., S.L.E., A.J.W., S.G.-J., F.W., B.S. and P.G. All authors have read and agreed to the published version of the manuscript.

Funding: We thank Nutricia New Zealand for funding this study. Microbiota analysis was funded by the Ministry of Business, Innovation and Employment (C11X1312), New Zealand.

Acknowledgments: We are grateful to the mothers and infants for their participation in this study. We thank Juliet Ansell, Greg Ward and Beneace Steffens for project initiation, and Thanuja Herath and Genelle Healey for technical assistance.

Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

References

- 1. Sommer, F.; Backhed, F. The gut microbiota—Masters of host development and physiology. *Nat. Rev. Microbiol.* **2013**, *11*, 227–238. [CrossRef]
- 2. Di Giulio, D.B.; Romero, R.; Kusanovic, J.P.; Gómez, R.; Kim, C.J.; Seok, K.S.; Gotsch, F.; Mazaki-Tovi, S.; Vaisbuch, E.; Sanders, K.; et al. Prevalence and diversity of microbes in the amniotic fluid, the fetal inflammatory response, and pregnancy outcome in women with preterm pre-labor rupture of membranes. *Am. J. Reprod. Immunol.* **2010**, *64*, 38–57.
- 3. Dominguez-Bello, M.G.; Costello, E.K.; Contreras, M.; Magris, M.; Hidalgo, G.; Fierer, N.; Knight, R. Delivery mode shapes the acquisition and structure of the initial microbiota across multiple body habitats in newborns. *Proc. Natl. Acad. Sci. USA* **2010**, *107*, 11971–11975. [CrossRef] [PubMed]
- 4. Ferretti, P.; Pasolli, E.; Tett, A.; Asnicar, F.; Gorfer, V.; Fedi, S.; Armanini, F.; Truong, D.T.; Manara, S.; Zolfo, M.; et al. Mother to infant microbial transmission from different body sites shapes the developing infant gut microbiome. *Cell Host Microbe* **2018**, *24*, 133–145. [CrossRef] [PubMed]
- 5. Calatayud, M.; Koren, O.; Collado, M.C. Maternal microbiome and metabolic health program microbiome development and health of the offspring. *Trends Endocrinol. Metab.* **2019**, *30*, 735–744. [CrossRef]
- Kumar, H.; du Toit, E.; Kulkarni, A.; Aakko, J.; Linderborg, K.M.; Zhang, Y.; Nicol, M.P.; Isolauri, E.; Yang, B.; Collado, M.C.; et al. Distinct patterns in human milk microbiota and fatty acid profiles across specific geographic locations. *Front. Microbiol.* 2016, 7, 1619. [CrossRef] [PubMed]
- Hermansson, H.; Kumar, H.; Collado, M.C.; Salminen, S.; Isolauri, E.; Rautava, S. Breast milk microbiota is shaped by mode of delivery and intrapartum antibiotic exposure. *Front. Nutr.* 2019, *6*, 4. [CrossRef] [PubMed]
- 8. Pannaraj, P.S.; Li, F.; Cerini, C.; Bender, J.M.; Yang, S.; Rollie, A.; Adisetiyo, H.; Zabih, S.; Lincez, P.J.; Bittinger, K.; et al. Association between breast milk bacterial communities and establishment and development of the infant gut microbiome. *JAMA Pediatr.* **2017**, *171*, 647–654. [CrossRef] [PubMed]
- 9. Lackey, K.A.; Williams, J.E.; Meehan, C.L.; Zachek, J.A.; Benda, E.D.; Price, W.J.; Foster, J.A.; Sellen, D.W.; Kamau-Mbuthia, E.W.; Kamundia, E.W.; et al. What's normal? Microbiomes in human milk and infant feces are related to each other but vary geographically: The inspire study. *Front. Nutr.* **2019**, *6*, 45. [CrossRef]
- 10. Van den Elsen, L.W.J.; Garssen, J.; Burcelin, R.; Verhasselt, V. Shaping the gut microbiota by breastfeeding: The gateway to allergy prevention? *Front. Pediatr.* **2019**, *7*, 47. [CrossRef] [PubMed]

- 11. Turfkruyer, M.; Verhasselt, V. Breast milk and its impact on maturation of the neonatal immune system. *Curr. Opin. Infect. Dis.* **2015**, *28*, 199–206. [CrossRef] [PubMed]
- 12. Frost, B.L.; Jilling, T.; Lapin, B.; Maheshwari, A.; Caplan, M.S. Maternal breast milk transforming growth factor-beta and feeding intolerance in preterm infants. *Pediatr. Res.* **2014**, *76*, 386–393. [CrossRef] [PubMed]
- 13. Smilowitz, J.T.; Lebrilla, C.B.; Mills, D.A.; German, J.B.; Freeman, S.L. Breast milk oligosaccharides: Structure-function relationships in the neonate. *Annu. Rev. Nutr.* **2014**, *34*, 143–169. [CrossRef] [PubMed]
- 14. Jackson, K.M.; Nazar, A.M. Breastfeeding, the immune response, and long-term health. *J. Am. Osteopath. Assoc.* **2006**, *106*, 203–207. [PubMed]
- 15. Rogier, E.W.; Frantz, A.L.; Bruno, M.E.C.; Wedlund, L.; Cohen, D.A.; Stromberg, A.J.; Kaetzel, C.S. Secretory antibodies in breast milk promote long-term intestinal homeostasis by regulating the gut microbiota and host gene expression. *Proc. Natl. Acad. Sci. USA* **2014**, *111*, 3074–3079. [CrossRef] [PubMed]
- 16. Statistics New Zealand. 2013 Census Quickstats about Culture and Identity; Statistics New Zealand: Wellington, New Zealand, 2014.
- 17. Butts, C.A.; Hedderley, D.I.; Herath, T.D.; Paturi, G.; Glyn-Jones, S.; Wiens, F.; Stahl, B.; Gopal, P. Human milk composition and dietary intakes of breastfeeding women of different ethnicity from the manawatu-wanganui region of new zealand. *Nutrients* **2018**, *10*, 1231. [CrossRef]
- Herlemann, D.P.R.; Labrenz, M.; Jürgens, K.; Bertilsson, S.; Waniek, J.J.; Andersson, A.F. Transitions in bacterial communities along the 2000 km salinity gradient of the baltic sea. *ISME J.* 2011, *5*, 1571–1579. [CrossRef] [PubMed]
- 19. Caporaso, J.G.; Kuczynski, J.; Stombaugh, J.; Bittinger, K.; Bushman, F.D.; Costello, E.K.; Fierer, N.; Pena, A.G.; Goodrich, J.K.; Gordon, J.I. Qiime allows analysis of high-throughput community sequencing data. *Nat. Methods* **2010**, *7*, 335–336. [CrossRef]
- 20. Masella, A.P.; Bartram, A.K.; Truszkowski, J.M.; Brown, D.G.; Neufeld, J.D. Pandaseq: Paired-end assembler for illumina sequences. *BMC Bioinform.* **2012**, *13*, 31. [CrossRef]
- 21. Edgar, R.C. Search and clustering orders of magnitude faster than blast. *Bioinformatics* **2010**, *26*, 2460–2461. [CrossRef]
- 22. Edgar, R.C.; Haas, B.J.; Clemente, J.C.; Quince, C.; Knight, R. Uchime improves sensitivity and speed of chimera detection. *Bioinformatics* 2011, 27, 2194–2200. [CrossRef] [PubMed]
- 23. Caporaso, J.G.; Bittinger, K.; Bushman, F.D.; DeSantis, T.Z.; Andersen, G.L.; Knight, R. Pynast: A flexible tool for aligning sequences to a template alignment. *Bioinformatics* **2010**, *26*, 266–267. [CrossRef] [PubMed]
- 24. DeSantis, T.Z.; Hugenholtz, P.; Larsen, N.; Rojas, M.; Brodie, E.L.; Keller, K.; Huber, T.; Dalevi, D.; Hu, P.; Andersen, G.L. Greengenes, a chimera-checked 16s rrna gene database and workbench compatible with arb. *Appl. Environ. Microbiol.* **2006**, *72*, 5069–5072. [CrossRef] [PubMed]
- 25. Lozupone, C.; Knight, R. Unifrac: A new phylogenetic method for comparing microbial communities. *Appl. Environ. Microbiol.* **2005**, *71*, 8228–8235. [CrossRef] [PubMed]
- 26. Vazquez-Baeza, Y.; Pirrung, M.; Gonzalez, A.; Knight, R. Emperor: A tool for visualizing high-throughput microbial community data. *GigaScience* **2013**, *2*, 16. [CrossRef]
- 27. Ministry of Health. *Food and Nutrition Guidelines for Healthy Pregnant and Breastfeeding Women: A Background Paper;* Ministry of Health: Wellington, New Zealand, 2006.
- 28. Ruiz, L.; García-Carral, C.; Rodriguez, J.M. Unfolding the human milk microbiome landscape in the omics era. *Front. Microbiol.* **2019**, *10*, 1378. [CrossRef]
- 29. Aaltonen, J.; Ojala, T.; Laitinen, K.; Poussa, T.; Ozanne, S.; Isolauri, E. Impact of maternal diet during pregnancy and breastfeeding on infant metabolic programming: A prospective randomized controlled study. *Eur. J. Clin. Nutr.* **2011**, 65, 10–19. [CrossRef]
- 30. Rodriguez, J.M.; Murphy, K.; Stanton, C.; Ross, R.P.; Kober, O.I.; Juge, N.; Avershina, E.; Rudi, K.; Narbad, A.; Jenmalm, M.C.; et al. The composition of the gut microbiota throughout life, with an emphasis on early life. *Microb. Ecol. Health Dis.* **2015**, *26*, 26050. [CrossRef]
- Jeurink, P.V.; Knipping, K.; Wiens, F.; Baranska, K.; Stahl, B.; Garssen, J.; Krolak-Olejnik, B. Importance of maternal diet in the training of the infant's immune system during gestation and lactation. *Crit. Rev. Food Sci. Nutr.* 2019, 59, 1311–1319. [CrossRef]
- 32. Lee, S.A.; Lim, J.Y.; Kim, B.-S.; Cho, S.J.; Kim, N.Y.; Kim, O.B.; Kim, Y. Comparison of the gut microbiota profile in breast-fed and formula-fed Korean infants using pyrosequencing. *Nutr. Res. Pract.* **2015**, *9*, 242–248. [CrossRef]

- Guaraldi, F.; Salvatori, G. Effect of breast and formula feeding on gut microbiota shaping in newborns. Front. Cell Infect. Microbiol. 2012, 2, 94. [CrossRef] [PubMed]
- 34. Dogra, S.; Sakwinska, O.; Soh, S.-E.; Ngom-Bru, C.; Brück, W.M.; Berger, B.; Brüssow, H.; Lee, Y.S.; Yap, F.; Chong, Y.-S.; et al. Dynamics of infant gut microbiota are influenced by delivery mode and gestational duration and are associated with subsequent adiposity. *mBio* **2015**, *6*, e02419. [CrossRef] [PubMed]
- Gomez-Arango, L.F.; Barrett, H.L.; Wilkinson, S.A.; Callaway, L.K.; McIntyre, H.D.; Morrison, M.; Dekker Nitert, M. Low dietary fiber intake increases collinsella abundance in the gut microbiota of overweight and obese pregnant women. *Gut Microbes* 2018, *9*, 189–201. [CrossRef] [PubMed]
- 36. Gallardo-Becerra, L.; Cornejo-Granados, F.; García-López, R.; Valdez-Lara, A.; Bikel, S.; Canizales-Quinteros, S.; López-Contreras, B.E.; Mendoza-Vargas, A.; Nielsen, H.; Ochoa-Leyva, A. Metatranscriptomic analysis to define the secrebiome, and 16s rrna profiling of the gut microbiome in obesity and metabolic syndrome of mexican children. *Microb. Cell Factories* **2020**, *19*, 61. [CrossRef] [PubMed]
- 37. Agarwal, S.; Karmaus, W.; Davis, S.; Gangur, V. Immune markers in breast milk and fetal and maternal body fluids: A systematic review of perinatal concentrations. *J. Hum. Lact.* **2011**, *27*, 171–186. [CrossRef]
- 38. Dawod, B.; Marshall, J.S. Cytokines and soluble receptors in breast milk as enhancers of oral tolerance development. *Front. Immunol.* **2019**, *10*, 16. [CrossRef]
- 39. Bottcher, M.F.; Jenmalm, M.C.; Garofalo, R.P.; Bjorksten, B. Cytokines in breast milk from allergic and nonallergic mothers. *Pediatr. Res.* 2000, 47, 157–162. [CrossRef]
- 40. Castellote, C.; Casillas, R.; Ramírez-Santana, C.; Pérez-Cano, F.J.; Castell, M.; Moretones, M.G.; López-Sabater, M.C.; Franch, A. Premature delivery influences the immunological composition of colostrum and transitional and mature human milk. *J. Nutr.* **2011**, *141*, 1181–1187. [CrossRef]
- 41. Collado, M.C.; Laitinen, K.; Salminen, S.; Isolauri, E. Maternal weight and excessive weight gain during pregnancy modify the immunomodulatory potential of breast milk. *Pediatr. Res.* **2012**, *72*, 77–85. [CrossRef]
- 42. Ohtsuka, Y.; Sanderson, I.R. Transforming growth factor-β: An important cytokine in the mucosal immune response. *Curr. Opin. Gastroenterol.* **2000**, *16*, 541–545. [CrossRef]
- Snijders, B.E.P.; Stelma, F.F.; Reijmerink, N.E.; Thijs, C.; Van Der Steege, G.; Damoiseaux, J.G.M.C.; Van Den Brandt, P.A.; Van Ree, R.; Postma, D.S.; Koppelman, G.H. Cd14 polymorphisms in mother and infant, soluble cd14 in breast milk and atopy development in the infant (koala study). *Pediatr. Allergy Immunol.* 2010, 21, 541–549. [CrossRef] [PubMed]
- Amoudruz, P.; Holmlund, U.; Schollin, J.; Sverremark-Ekström, E.; Montgomery, S.M. Maternal country of birth and previous pregnancies are associated with breast milk characteristics. *Pediatr. Allergy Immunol.* 2009, 20, 19–29. [CrossRef] [PubMed]
- Holmlund, U.; Amoudruz, P.; Johansson, M.A.; Haileselassie, Y.; Ongoiba, A.; Kayentao, K.; Traoré, B.; Doumbo, S.; Schollin, J.; Doumbo, O.; et al. Maternal country of origin, breast milk characteristics and potential influences on immunity in offspring. *Clin. Exp. Allergy* 2010, *162*, 500–509. [CrossRef] [PubMed]
- Ballard, O.; Morrow, A.L. Human milk composition: Nutrients and bioactive factors. *Pediatr. Clin. N. Am.* 2013, 60, 49–74. [CrossRef] [PubMed]
- 47. Ngom, P.T.; Collinson, A.C.; Pido-Lopez, J.; Henson, S.M.; Prentice, A.M.; Aspinall, R. Improved thymic function in exclusively breastfed infants is associated with higher interleukin 7 concentrations in their mothers' breast milk. *Am. J. Clin. Nutr.* **2004**, *80*, 722–728. [CrossRef] [PubMed]
- 48. Aspinall, R.; Prentice, A.M.; Ngom, P.T. Interleukin 7 from maternal milk crosses the intestinal barrier and modulates t-cell development in offspring. *PLoS ONE* **2011**, *6*, e20812. [CrossRef] [PubMed]



© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).